Last reviewed 2026-04-22 · How we verify

Copper Cu 64 PSMA I&T

Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment.

Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment. Used for Prostate cancer (imaging and therapeutic indication), PSMA-positive metastatic castration-resistant prostate cancer.

At a glance

Mechanism of action

This radiopharmaceutical uses copper-64, a positron-emitting isotope, conjugated to a PSMA-targeting ligand to enable both PET imaging and therapeutic delivery in PSMA-expressing tumors. The agent localizes to prostate cancer cells and other PSMA-positive malignancies, allowing for visualization and potential therapeutic irradiation. Cu-64's dual imaging and therapeutic capability (theranostic approach) enables both diagnostic assessment and treatment planning.

Approved indications

• Prostate cancer (imaging and therapeutic indication)
• PSMA-positive metastatic castration-resistant prostate cancer

Common side effects

• Radiation-related toxicity
• Hematologic effects
• Nausea
• Fatigue

Key clinical trials

• Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (PHASE3)
• Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (PHASE3)
• Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.